Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease

[1] Catt H(2019)Systematic review: outcomes and adverse events from randomised trials in Crohn’s disease (in eng) Aliment Pharmacol Ther 49 978-996

[2] Hughes D(2020)Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial, (in eng) Lancet Gastroenterol Hepatol 5 1063-1075

[3] Kirkham JJ(2020)Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis (in eng) Gastroenterology 158 550-561

[4] Bodger K(2020)Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study The Lancet Gastroenterology & Hepatology 5 819-828

[5] Atreya R(1976)Development of a Crohn’s Disease Activity Index. National Cooperative Crohn’s Disease Study (in eng) Gastroenterology 70 439-444

[6] Sandborn WJ(2015)A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity, (in eng) Alimentary pharmacology & therapeutics 41 77-86

[7] Feagan BG(2020)Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis Alimentary Pharmacology & Therapeutics 51 1047-1066

[8] Best WR(2019)Ustekinumab as induction and maintenance therapy for ulcerative colitis New England Journal of Medicine 381 1201-1214

[9] Becktel JM(2019)Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials, (in eng) Clin Gastroenterol Hepatol 17 1541-1550

[10] Singleton JW(2018)Prognostic value of histological activity in patients with ulcerative colitis in deep remission: a prospective multicenter study, (in eng) United European Gastroenterol J 6 765-772

[1] Catt H(2019)Systematic review: outcomes and adverse events from randomised trials in Crohn’s disease (in eng) Aliment Pharmacol Ther 49 978-996

[2] Hughes D(2020)Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial, (in eng) Lancet Gastroenterol Hepatol 5 1063-1075

[3] Kirkham JJ(2020)Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis (in eng) Gastroenterology 158 550-561

[4] Bodger K(2020)Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study The Lancet Gastroenterology & Hepatology 5 819-828

[5] Atreya R(1976)Development of a Crohn’s Disease Activity Index. National Cooperative Crohn’s Disease Study (in eng) Gastroenterology 70 439-444

[6] Sandborn WJ(2015)A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity, (in eng) Alimentary pharmacology & therapeutics 41 77-86

[7] Feagan BG(2020)Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis Alimentary Pharmacology & Therapeutics 51 1047-1066

[8] Best WR(2019)Ustekinumab as induction and maintenance therapy for ulcerative colitis New England Journal of Medicine 381 1201-1214

[9] Becktel JM(2019)Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials, (in eng) Clin Gastroenterol Hepatol 17 1541-1550

[10] Singleton JW(2018)Prognostic value of histological activity in patients with ulcerative colitis in deep remission: a prospective multicenter study, (in eng) United European Gastroenterol J 6 765-772